Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 16;36(6):415-422.
doi: 10.1055/s-0043-1767705. eCollection 2023 Nov.

Impact of Molecular Status on Cytoreductive Surgery for Peritoneal Metastases from Colorectal Cancer

Yun Zhong  1   2   3   4   5 , Keli Yang  1   2   3   4   5 , Xiusen Qin  1   2   3   4   5 , Rui Luo  1   2   3   4   5 , Hui Wang  1   2   3   4   5
Affiliations
Review

Impact of Molecular Status on Cytoreductive Surgery for Peritoneal Metastases from Colorectal Cancer

Yun Zhong et al. Clin Colon Rectal Surg. .

Abstract

Colorectal cancer peritoneal metastases (CRC-PM) are present in 5 to 15% of instances of CRC, and the overall survival (OS) of patients with CRC-PM is much lower than that of patients with other isolated metastatic locations. In recent years, the introduction of cytoreductive surgery (CRS) in conjunction with hyperthermic intraperitoneal chemotherapy has resulted in a significant improvement in CRC-PM patients' OS. Despite this, a significant proportion of CRS patients continue to suffer complications of grades III to V or even die during the perioperative period. Early diagnosis, optimization of patient selection criteria, and refining of individualized combination therapy are necessary for these patients. In this review, we evaluate studies examining the relationship between molecular status and CRS in CRC-PM. Our objective is to gain a comprehensive understanding of how the altered molecular status of CRC-PM impacts CRS, which could increase the likelihood of tailored therapy in the future.

Keywords: biomarkers; colorectal cancer; cytoreductive surgery; molecular status; peritoneal metastasis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest None declared.

Figures

Fig. 1
Fig. 1
Cytoreductive surgery for patients with peritoneal metastases from colorectal cancer.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sung H, Ferlay J, Siegel R L et al.Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(03):209–249. - PubMed
    1. Bray F, Ferlay J, Soerjomataram I, Siegel R L, Torre L A, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(06):394–424. - PubMed
    1. Arnold M, Sierra M S, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(04):683–691. - PubMed
    1. Bhat A A, Nisar S, Singh M et al.Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: emerging avenue for targeted therapy. Cancer Commun (Lond) 2022;42(08):689–715. - PMC - PubMed
    1. Koppe M J, Boerman O C, Oyen W JG, Bleichrodt R P. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg. 2006;243(02):212–222. - PMC - PubMed

Grants and funding

Funding This study is supported by National Key Clinical Discipline, the Guangzhou Science and Technology Bureau, Guangzhou, China (2023A04J2245), and the Sixth Affiliated Hospital, Sun Yat-Sen University Clinical Research –‘1010’Program:1010CG(2022)-08.